Results 181 to 190 of about 101,135 (306)

Acute Stroke Patients on Daily Anticoagulant or Antiplatelet Therapy Receiving Thrombolysis or Thrombectomy. [PDF]

Cureus
Alter SM, Phadnis S, Mirza Z, Solano JJ, Shih RD, Hughes PG, Clayton LM.   +6 more
europepmc   +1 more source

P‐CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In patients with atherothrombotic disease on antithrombotic therapy, P‐CABs demonstrated a significantly superior protective effect against clinically significant upper GI haemorrhage compared to PPIs (aHR 0.22; p = 0.016). This real‐world study highlights P‐CABs as a more potent gastroprotective strategy for high‐risk populations requiring intensive ...
Min Joo Yoon, Soyoung Lee, Hye‐Kyung Jung, Min‐ho Kim, Suna Yu, Eui Sun Jeong, Chung Hyun Tae   +6 more
wiley   +1 more source

Reinitiating antiplatelet therapy in chronic subdural hematoma: Does adjunctive middle meningeal artery embolization improve outcomes? [PDF]

Neurosurg Rev
Essibayi MA, Kakadiya J, Salim HA, Chen H, Azzam AY, Dmytriw AA, Yedavalli VS, Kassar MA, Colasurdo M, Gandhi D, Khatri D, Haranhalli N, Altschul DJ, Lakhani DA.   +13 more
europepmc   +1 more source

Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real‐world study in Quebec

British Journal of Haematology, EarlyView.
Summary Haemoglobin SC (HbSC) disease is the second most prevalent form of sickle cell disease, but evidence for hydroxyurea (hydroxycarbamide; HU) to prevent pain episodes was limited until the prospective identification of variables as outcomes for treatment (PIVOT) trial.
Alice Girard, Laurianne Charette, Mélissa Haouchine, Laurence Bozec, Mohamed Zakaria Bachir Bouyadjera, Mariane Poitras, Vincent‐Thierry Taillefer, Chloé Trudeau, Yves Pastore, Nathalie Letarte, Stéphanie Forté   +10 more
wiley   +1 more source

Practicing Doctors' Awareness and Perception of Tooth Extraction Risks in Patients on Antiplatelet Therapy. [PDF]

Int J Clin Pediatr Dent
Alqahtani AS, Ali FM, Hezam AAA, Iryani GM, Sahary AA, Gadi AAM, Moafa MK, Shanab HG, Hassan AAA.   +8 more
europepmc   +1 more source

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source

Indobufen Dual Antiplatelet Therapy (DAPT) Versus Aspirin Dual Antiplatelet Therapy (DAPT) After Percutaneous Coronary Intervention (PCI): A Systematic Review and Meta-Analysis. [PDF]

Catheter Cardiovasc Interv
Saeed O, Saeed A, Barakat O, Bawjeh A, Saka T, Yousif TM, Adim AM, Elhadi M, Mamas MA.   +8 more
europepmc   +1 more source

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

British Journal of Pharmacology, EarlyView.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden, Loes C. Oskam, Lenny van Bon, Chantal P. Rovers   +3 more
wiley   +1 more source

De‐Implementing Low‐Value Care in Dentistry: The Case for Choosing Wisely Campaigns

Community Dentistry and Oral Epidemiology, EarlyView.
ABSTRACT De‐implementation refers to the practice within implementation science that targets reducing low‐value care; that is practices that have been proven to be outdated, unnecessary, potentially harmful and in some cases not cost‐efficient. Reducing and removing habitual practices, as well as introducing new care, is not easy, as there are multiple
Fabio Arriola‐Pacheco, Rafael Aiello Bomfim, Karen Born, Herenia P. Lawrence   +3 more
wiley   +1 more source

Garadacimab for the long‐term prophylaxis of hereditary angioedema

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Hereditary angioedema (HAE), a rare and debilitating disease characterized by recurrent and spontaneous attacks of tissue swelling, has a high unmet therapeutic need, with many patients experiencing insufficient disease control with current prophylactic treatments.
Emel Aygören‐Pürsün, Regina Treudler, Petra Staubach, Inmaculada Martinez Saguer, Thomas Linhoff, Markus Magerl   +5 more
wiley   +1 more source